Skip to main content
Fig. 2 | Renal Replacement Therapy

Fig. 2

From: An exploratory clinical trial on the efficacy and safety of glucagon-like peptide-1 receptor agonist dulaglutide in patients with type 2 diabetes on maintenance hemodialysis

Fig. 2

Changes in GA and HbA1c values during this study. GA and HbA1c values showed a tendency to decrease from four weeks after the start of the use of dulaglutide. Data are presented as median with an interquartile range. Δ indicates changes from baseline to each month. Number of subjects available for 0, 4, 8, 12, 16, 20, 24 week-measurements was 12, 10, 12, 10, 12, 11, and 12 for GA and 11, 11, 11, 11, 10, 11, and 9 for HbA1c, respectively. GA, glycated albumin; HbA1c, glycated hemoglobin

Back to article page

Renal Replacement Therapy

ISSN: 2059-1381

Contact us